Ann E Woolfrey
Overview
Explore the profile of Ann E Woolfrey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
1811
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kornblit B, Storer B, Andersen N, Maris M, Chauncey T, Petersdorf E, et al.
Blood
. 2020 Jul;
136(13):1499-1506.
PMID: 32603426
This trial aimed to evaluate the efficacy of sirolimus in addition to cyclosporine (CSP) and mycophenolate mofetil (MMF) for graft-versus-host disease (GVHD) prophylaxis after nonmyeloablative conditioning for HLA class I...
2.
Cooper J, Storer B, Granot N, Gyurkocza B, Sorror M, Chauncey T, et al.
Haematologica
. 2020 Jun;
106(6):1599-1607.
PMID: 32499241
We have used a non-myeloablative conditioning regimen for allogeneic hematopoietic cell transplantation for the past twenty years. During that period, changes in clinical practice have been aimed at reducing morbidity...
3.
Mallhi K, Srikanthan M, Baker K, Frangoul H, Torgerson T, Petrovic A, et al.
Biol Blood Marrow Transplant
. 2020 Apr;
26(7):1332-1341.
PMID: 32234377
Allogeneic hematopoietic cell transplant (HCT) is often the only curative therapy for patients with nonmalignant diseases; however, many patients do not have an HLA-matched donor. Historically, poor survival has been...
4.
Weisdorf D, Cooley S, Wang T, Trachtenberg E, Vierra-Green C, Spellman S, et al.
Blood Adv
. 2020 Feb;
4(4):740-754.
PMID: 32092137
Natural killer (NK) cell recognition and killing of target cells are enhanced when inhibitory killer immunoglobulin-like receptors (KIR) are unable to engage their cognate HLA class I ligands. The genes...
5.
Bader P, Salzmann-Manrique E, Balduzzi A, Dalle J, Woolfrey A, Bar M, et al.
Blood Adv
. 2019 Nov;
3(21):3393-3405.
PMID: 31714961
Detection of minimal residual disease (MRD) pre- and post-hematopoietic cell transplantation (HCT) for pediatric acute lymphoblastic leukemia (ALL) has been associated with relapse and poor survival. Published studies have had...
6.
Bejanyan N, Kim S, Hebert K, Kekre N, Abdel-Azim H, Ahmed I, et al.
Blood Adv
. 2019 Oct;
3(20):3123-3131.
PMID: 31648332
Allogeneic bone marrow transplantation (BMT) is curative therapy for the treatment of patients with severe aplastic anemia (SAA). However, several conditioning regimens can be used for BMT. We evaluated transplant...
7.
Sandmaier B, Kornblit B, Storer B, Olesen G, Maris M, Langston A, et al.
Lancet Haematol
. 2019 Jun;
6(8):e409-e418.
PMID: 31248843
Background: Acute graft-versus-host-disease (GVHD) after non-myeloablative human leucocyte antigen (HLA)-matched, unrelated donor, allogeneic haemopoietic stem cell transplantation (HSCT) is associated with considerable morbidity and mortality. This trial aimed to evaluate...
8.
Elsawy M, Storer B, Milano F, Sandmaier B, Delaney C, Salit R, et al.
Biol Blood Marrow Transplant
. 2018 Dec;
25(5):1045-1052.
PMID: 30500442
The Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) was developed and validated to weigh the burden of pretransplantation comorbidities and estimate their impact on post-transplantation risks of nonrelapse mortality (NRM). Recently,...
9.
Chhabra S, Ahn K, Hu Z, Jain S, Assal A, cerny J, et al.
Blood Adv
. 2018 Nov;
2(21):2922-2936.
PMID: 30396912
Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment of chronic myeloid leukemia (CML). Optimal conditioning intensity for allo-HCT for CML in the era of tyrosine kinase inhibitors (TKIs)...
10.
Pahnke S, Egeland T, Halter J, Hagglund H, Shaw B, Woolfrey A, et al.
Bone Marrow Transplant
. 2018 Oct;
54(6):858-866.
PMID: 30283148
Despite biosimilars of the granulocyte-colony stimulating factor (G-CSF) filgrastim being approved by the European Medicines Agency since 2008, there is still some debate regarding their use in related and unrelated...